199 related articles for article (PubMed ID: 34445291)
21. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract][Full Text] [Related]
22. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.
Jay SM; Murthy AC; Hawkins JF; Wortzel JR; Steinhauser ML; Alvarez LM; Gannon J; Macrae CA; Griffith LG; Lee RT
Circulation; 2013 Jul; 128(2):152-61. PubMed ID: 23757312
[TBL] [Abstract][Full Text] [Related]
23. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
24. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
25. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
26. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
27. SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells.
De Angelis A; Piegari E; Cappetta D; Russo R; Esposito G; Ciuffreda LP; Ferraiolo FA; Frati C; Fagnoni F; Berrino L; Quaini F; Rossi F; Urbanek K
Int J Cardiol; 2015; 189():30-44. PubMed ID: 25889431
[TBL] [Abstract][Full Text] [Related]
28. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
29. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes.
Dimitrakis P; Romay-Ogando MI; Timolati F; Suter TM; Zuppinger C
Cell Tissue Res; 2012 Nov; 350(2):361-72. PubMed ID: 22864983
[TBL] [Abstract][Full Text] [Related]
30. Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux.
Zhang X; Peng X; Yu W; Hou S; Zhao Y; Zhang Z; Huang X; Wu K
Cancer Lett; 2011 Aug; 307(2):174-81. PubMed ID: 21536373
[TBL] [Abstract][Full Text] [Related]
31. Naked and Decorated Nanoparticles Containing H
Peira E; Chirio D; Sapino S; Chegaev K; Chindamo G; Salaroglio IC; Riganti C; Gallarate M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232858
[TBL] [Abstract][Full Text] [Related]
32. Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Pettke A; Hotfilder M; Clemens D; Klco-Brosius S; Schaefer C; Potratz J; Dirksen U
Anticancer Drugs; 2016 Nov; 27(10):1001-10. PubMed ID: 27487911
[TBL] [Abstract][Full Text] [Related]
33. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.
Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D
Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751
[TBL] [Abstract][Full Text] [Related]
34. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
36. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Gonçalves C; Martins-Neves SR; Paiva-Oliveira D; Oliveira VE; Fontes-Ribeiro C; Gomes CM
Life Sci; 2015 Jun; 130():47-56. PubMed ID: 25818183
[TBL] [Abstract][Full Text] [Related]
37. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.
Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109
[TBL] [Abstract][Full Text] [Related]
38. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896
[TBL] [Abstract][Full Text] [Related]
39. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
